APR 24, 2020 1:44 AM PDT

Drug Targets Hard To Treat Uterine Cancer

WRITTEN BY: Nouran Amin

A clinical trial was deemed successful when evaluating a therapeutic for a hard-to-treat form of uterine cancer. The drug caused DNA damage inside tumors resulting in shrinkage for about one-third of patients.

“The preliminary results, to be presented online at Thursday's virtual session of the Society for Gynecologic Oncology (SGO) Annual Meeting on Women's Cancer, demonstrated strong activity of WEE1-directed therapy in uterine serous carcinoma (USC), which accounts for about 10% of uterine cancers but up to 40% of deaths from the disease” trial leaders say.

The drug is called ‘adavosertib’ and works by stopping DNA from replicating in the tumor cells. Specifically, it targets a protein called WEE1 that is involved in the replication process. Some side-effects of the drug include anemia, diarrhea, nausea, and fatigue.

Learn more about uterine cancer (also known as endometrial cancer):

"Adavosertib demonstrated remarkable activity as a single agent in this group of patients," says the study's lead author, Joyce Liu, MD, MPH, of Dana-Farber. "It's especially encouraging in a disease such as USC, for which current treatments are of limited effectiveness."

The study involved 35 participants all of whom who underwent platinum-based chemotherapy.

“In some cases, the responses were exceptionally durable, with some patients still responding more than a year after undergoing treatment,” study leaders say.

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUL 23, 2020
Cardiology
Protecting the Heart After a Heart Attack
JUL 23, 2020
Protecting the Heart After a Heart Attack
Cardiovascular disease accounts for thirty percent of mortalities around the world. These diseases start small and slowl ...
AUG 21, 2020
Immunology
Cancer Feels the STING
AUG 21, 2020
Cancer Feels the STING
Researchers have discovered a protein that can amplify immune reactions against tumors. The stimulator of interferon gen ...
AUG 22, 2020
Drug Discovery & Development
New Class of Antibiotics Could Treat UTIs
AUG 22, 2020
New Class of Antibiotics Could Treat UTIs
At 11 million cases annually, urinary tract infections (UTIs) are the most common outpatient infections in the U.S., Sci ...
AUG 31, 2020
Cancer
Targeting Your Inner Hedgehog to Fight Chemoresistance in Colorectal Cancer
AUG 31, 2020
Targeting Your Inner Hedgehog to Fight Chemoresistance in Colorectal Cancer
Chemoresistance is a serious problem for many cancer therapies. Solutions to this problem are harder to come by than the ...
SEP 08, 2020
Drug Discovery & Development
New Drug Boosts Bone Growth in Children with Dwarfism
SEP 08, 2020
New Drug Boosts Bone Growth in Children with Dwarfism
A Phase III global clinical trial by the Murdoch Children’s Research Institute (MCRI) has found that a new drug, k ...
SEP 01, 2020
Drug Discovery & Development
First Novel Compounds to Inhibit Cancer-Linked Enzymes
SEP 01, 2020
First Novel Compounds to Inhibit Cancer-Linked Enzymes
Researchers from the University of Michigan Rogel Cancer Center have worked on creating a therapeutic-based compound tha ...
Loading Comments...